JOHNSON & JOHNSON
JNJ · CIK 0000200406 · Pharmaceutical Preparations
About JOHNSON & JOHNSON
General Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field.
Business information sourced from SEC annual filing filed Feb 11, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.
Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.
Financial highlights
Latest qualifying annual SEC observations · USDHistorical financial performance
USD billions · Annual SEC observations · Choose a metric
Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.
Annual financial history
USD · Exact fiscal period ends| Period ended | Revenue | Net income | Operating income | Assets | Liabilities | Cash | Operating cash flow | Net margin |
|---|---|---|---|---|---|---|---|---|
| Dec. 28, 2025 | $94.19B | $26.80B | — | $199.21B | $117.67B | $19.71B | $24.53B | 28.5% |
| Dec. 29, 2024 | $88.82B | $14.07B | — | $180.10B | $108.61B | $24.10B | $24.27B | 15.8% |
| Dec. 31, 2023 | $85.16B | $35.15B | — | $167.56B | $98.78B | $21.86B | $22.79B | 41.3% |
| Jan. 1, 2023 | $79.99B | $17.94B | — | $187.38B | $110.57B | $12.89B | $21.19B | 22.4% |
| Jan. 2, 2022 | $78.74B | $20.88B | — | $182.02B | $108.00B | $14.49B | $23.41B | 26.5% |
| Jan. 3, 2021 | $82.58B | $14.71B | — | $174.89B | $111.62B | $13.98B | $23.54B | 17.8% |
| Dec. 29, 2019 | $82.06B | $15.12B | — | $157.73B | $98.26B | $17.30B | $23.42B | 18.4% |
| Dec. 30, 2018 | $81.58B | $15.30B | — | $152.95B | $93.20B | $18.11B | $22.20B | 18.8% |
A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.
Company information
- Registered name
- JOHNSON & JOHNSON
- Ticker symbol
- JNJ
- CIK
- 0000200406
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC SIC code
- 2834
- Fiscal year end (MMDD)
- 0103
- Last SEC synchronization
- Nov 7, 2026 14:52 UTC
- Headquarters / business address
- ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 08933 - Mailing address
- ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 08933 - Business phone
- 732-524-2455
Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Last company information check: Nov 7, 2026 20:21 UTC. Official website, business descriptions and executive details require separate verification.
Latest SEC filings
Browse filings →| Form | Filed | Report period | Official source |
|---|---|---|---|
| 10-K | Feb. 11, 2026 | Dec. 28, 2025 | View SEC filing ↗ |
| 10-K | Feb. 13, 2025 | Dec. 29, 2024 | View SEC filing ↗ |
| 10-K | Feb. 16, 2024 | Dec. 31, 2023 | View SEC filing ↗ |
| 10-K | Feb. 16, 2023 | Jan. 1, 2023 | View SEC filing ↗ |
| 10-K | Feb. 17, 2022 | Jan. 2, 2022 | View SEC filing ↗ |
| 10-K | Feb. 22, 2021 | Jan. 3, 2021 | View SEC filing ↗ |
| 10-K | Feb. 18, 2020 | Dec. 29, 2019 | View SEC filing ↗ |
| 10-K | Feb. 20, 2019 | Dec. 30, 2018 | View SEC filing ↗ |
Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.